Tuesday Morning Pre-Market Insights: Shake Shack Inc (SHAK), Novavax, Inc. (NVAX), Celldex Therapeutics, Inc. (CLDX), Organovo Holdings Inc (ONVO)

By Kate George

Shake Shack Inc SHAK increased 7.87% in pre-market trading to $76.20 after the fast-casual burger restaurant released second quarter earnings. The company posted $48.5 million in quarterly revenue, beating the analyst estimate of $42.8 million and marking a 74.7% increase. Likewise, Shake Shack beat earnings and posted basic earnings per share of $0.09, beating the consensus of $0.03 and up from the $0.07 posted in the same quarter last year. Analysts were excited by Shake Shack's same-store sales figure, which increased 12.9% in the quarter compared to the 8.6% analysts were expecting. Looking forward, Shake Shack raised its revenue estimate for 2015 to $171 million to $174 million, up from the previous range of $161 million to $165 million. As of this writing, TipRanks has polled 5 analysts on SHAK in the last 3 months. Of the 5 analysts, 3 are neutral on the stock and 2 are bearish. The average 12-month price target is $44.25, marking a 37% potential downside from where shares last closed.

Novavax, Inc. NVAX shares soared 13.32% in pre-market trading to $12.68 after the biopharmaceutical company announced positive top-line data from the Phase 2 trial of RSV F-Protein Vaccine. RSV is a major respiratory pathogen in infants, children, and adults, though the study only tested the vaccine in older adults. The study proved that RSV was efficient in any population and demonstrated to prevent symptomatic RSV disease in older adults by a statistically significant margin. The vaccine was well-tolerated and met its primary, secondary, and exploratory endpoints. In addition to this new positive data, Novavax released second quarter earnings yesterday in which the company posted quarterly revenue of $14.0 million, marking a 69% year-over-year increase. According to TipRanks, 2 analysts have made bullish ratings on the stock in the last 3 months. On average, the 12-month price target is $12.50, marking an 11% potential upside from where the stock last closed.

Celldex Therapeutics, Inc. CLDX slipped 15% in pre-market trading down to $18.15 after the company reported a second quarter loss. The biopharmaceutical company posted a net loss of $32.4 million, or ($0.33) per share. In the same quarter of last year, the company posted a net loss of $28.3 million, or ($0.32) per share. Celldex currently has several pipeline therapies, such as RINTEGA, Varlilumab, and Glembatumumab vedotin; all of which are in pipeline testing. Looking forward, the company expects that it will have sufficient capital to fund its operating expenses through 2017. However, the company warns that this is dependent on clinical data results from the RINTEGA trials. As of this writing, TipRanks has polled 4 analysts on CLDX in the last 3 months. Of the 4 analysts, all of them are bullish on the stock. The average 12-month price target is $36, marking a 68% potential upside from where the stock last closed.

Organovo Holdings Inc ONVO shares plummeted -16.47% in pre-market trading down to $2.84 after the company reported a fiscal first quarter loss. The biopharmaceutical company that focuses on printing human tissue reported a loss of $8.5 million, compared to the loss of $6.4 million it posted in the same quarter a year prior. Operating expenses increased 35% year-over-year to $2.3 million. The company posted total revenue of $306,000, mostly derived from research agreements related to the exVive3D Human Liver Tissue. This was a 209% increase from the same quarter a year prior, when revenue was derived from existing partnerships and research grants. Following earnings, Caroline Corner of Cantor Fitzgerald downgraded the stock to Hold and slashed her price target from $6 to $3.50, commenting that sales for exVive3D Human Liver Tissue were underwhelming. According to TipRanks, 2 analysts have rated ONVO in the last 3 months, 1 giving the stock a bullish rating and the other a neutral rating. The average 12-month price target on the stock is $4.25, marking a 25% potential upside from where the stock last closed.